Huvepharma opens a new vaccine plant
A new plant for the production of veterinary vaccines now forms part of the Huvepharma facilities within the framework of Biovet-Razgrad. Biovet is one of the largest production companies in Bulgaria with over 70 years of history, traditions and expertise in the field of biotechnology. It owns three precision biotransformation plants in Peshtera, Razgrad and Botevgrad. With a capacity of over 10,000 cubic metres, it is the largest fermentation company in Europe. The company employs over 2,400 highly qualified biotechnologists, microbiologists, chemists, engineers and other employees.
The vaccine plant is modern and high-tech, equipped with the latest generation of machines and equipment. It is designed to be multifunctional, with several independent technological lines, which ensure flexibility and production efficiency.
The investment in the plant amounts to BGN 140 million. Its construction started at the end of 2019 and despite the severe situation with the Коронавирус pandemic, it did not stop and was completed in 4 years. That period saw the implementation of the design, engineering, delivery and installation of the equipment, tests and obtaining all the permits to carry out the activity.
The plant has a certificate of good production practice from the Bulgarian Food Safety Agency (BFSA), valid for the entire European Union. The facility has a total area of 12,000 sq.m., of which 8,000 sq.m. are clean rooms with different sanitary categorizations. Separate independent zones have been formed for the production of egg vaccines, bacterial vaccines and viral vaccines. There is a specialized area for the sterile filling of injection vials, lyophilization and product packaging.
Modern inspection and analysis laboratories have been built and equipped for quality control of the production process and the finished products. The production conditions even meet the standards for the production of human vaccines although Huvepharma specializes in medical products for animals. That is why the vaccines that will be produced in Razgrad will be used for industrial animal husbandry - for poultry, cattle and pigs.
Vaccine strains and technologies were developed in the research and development laboratory in Peshtera during the construction of the plant. These are now transferred to Razgrad. The only steps left to complete are the release of pilot validation batches, and the completion of product files and sales license issuance.
There are plans to reach regular production levels in 2 years. Currently, the plant employs 70 people, but in the coming years, at full capacity, it will exceed 300.
Profile
Huvepharma is a rapidly growing, fully integrated global pharmaceutical company with a focus on the development, manufacture and marketing of human and veterinary products. The company is a global leader in the field of coccidial products, nutritional feed additives, enzymes, niche veterinary products, probiotics and Omega 3. It has production sites in Razgrad, Peshtera and Botevgrad in Bulgaria, St. Louis (Missouri), Lincoln (Nebraska) in the USA, Garessio (Italy) and in France.
Huvepharma reaches the markets through its own subsidiaries and sales organizations in 25 countries and regions such as the USA, Belgium, Poland, Thailand, India, China, Taiwan, Brazil, Turkey, etc., as well as through specialized distributors in other markets. This sales and marketing network facilitates the company`s products and services to reach customers in over 100 countries worldwide.
The vaccine plant is modern and high-tech, equipped with the latest generation of machines and equipment. It is designed to be multifunctional, with several independent technological lines, which ensure flexibility and production efficiency.
The investment in the plant amounts to BGN 140 million. Its construction started at the end of 2019 and despite the severe situation with the Коронавирус pandemic, it did not stop and was completed in 4 years. That period saw the implementation of the design, engineering, delivery and installation of the equipment, tests and obtaining all the permits to carry out the activity.
The plant has a certificate of good production practice from the Bulgarian Food Safety Agency (BFSA), valid for the entire European Union. The facility has a total area of 12,000 sq.m., of which 8,000 sq.m. are clean rooms with different sanitary categorizations. Separate independent zones have been formed for the production of egg vaccines, bacterial vaccines and viral vaccines. There is a specialized area for the sterile filling of injection vials, lyophilization and product packaging.
Modern inspection and analysis laboratories have been built and equipped for quality control of the production process and the finished products. The production conditions even meet the standards for the production of human vaccines although Huvepharma specializes in medical products for animals. That is why the vaccines that will be produced in Razgrad will be used for industrial animal husbandry - for poultry, cattle and pigs.
Vaccine strains and technologies were developed in the research and development laboratory in Peshtera during the construction of the plant. These are now transferred to Razgrad. The only steps left to complete are the release of pilot validation batches, and the completion of product files and sales license issuance.
There are plans to reach regular production levels in 2 years. Currently, the plant employs 70 people, but in the coming years, at full capacity, it will exceed 300.
Profile
Huvepharma is a rapidly growing, fully integrated global pharmaceutical company with a focus on the development, manufacture and marketing of human and veterinary products. The company is a global leader in the field of coccidial products, nutritional feed additives, enzymes, niche veterinary products, probiotics and Omega 3. It has production sites in Razgrad, Peshtera and Botevgrad in Bulgaria, St. Louis (Missouri), Lincoln (Nebraska) in the USA, Garessio (Italy) and in France.
Huvepharma reaches the markets through its own subsidiaries and sales organizations in 25 countries and regions such as the USA, Belgium, Poland, Thailand, India, China, Taiwan, Brazil, Turkey, etc., as well as through specialized distributors in other markets. This sales and marketing network facilitates the company`s products and services to reach customers in over 100 countries worldwide.
Източник: economic.bg
КОМЕНТАРИ